Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 1, 2015, Pages 16-23

  Flaumenhaft, Robert ^a   Furie, Bruce ^a   Zwicker, Jeffrey I ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Blood platelet; platelet inhibitors; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; FLAVONOID; PROTEIN DISULFIDE ISOMERASE; QUERCETIN; RUTOSIDE; ENZYME INHIBITOR; FIBRIN; FIBRINOLYTIC AGENT;

BLOOD CLOTTING; BLOOD VESSEL INJURY; FIBRIN FORMATION; HUMAN; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; THROMBOCYTE;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; DRUG DESIGN; ENZYME INHIBITORS; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; PLATELET ACTIVATION; PROTEIN DISULFIDE-ISOMERASES; THROMBOSIS;

EID: 84920283235     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303410     Document Type: Review

References (68)

1. Butera D, Cook KM, Chiu J, Wong JW, Hogg PJ. Control of blood proteins by functional disulfde bonds. Blood. 2014;123:2000-2007.
2. Furie B, Flaumenhaft R. Thiol isomerases in thrombus formation. Circ Res. 2014;114:1162-1173.
3. Wang C, Li W, Ren J, Fang J, Ke H, Gong W, Feng W, Wang CC. Structural insights into the redox-regulated dynamic conformations of human protein disulfde isomerase. Antioxid Redox Signal. 2013;19:36-45.
4. Tian R, Li SJ, Wang DL, Zhao Z, Liu Y, He RQ. The acidic C-terminal domain stabilizes the chaperone function of protein disulfde isomerase. J Biol Chem. 2004;279:48830-48835.
5. Cai H, Wang CC, Tsou CL. Chaperone-like activity of protein disulfde isomerase in the refolding of a protein with no disulfde bonds. J Biol Chem. 1994;269:24550-24552.
6. Dai Y, Wang C. A mutant truncated protein disulfde isomerase with no chaperone activity. J Biol Chem. 1997;272:27572-27576.
7. Song JL, Wang CC. Chaperone-like activity of protein disulfde-isomerase in the refolding of rhodanese. Eur J Biochem. 1995;231:312-316.
8. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. 2006;441:513-517.
9. Uys JD, Xiong Y, Townsend DM. Nitrosative stress-induced S-glutathionylation of protein disulfde isomerase. Methods Enzymol. 2011;490:321-332.
10. Sliskovic I, Raturi A, Mutus B. Characterization of the S-denitrosation activity of protein disulfde isomerase. J Biol Chem. 2005;280:8733-8741.
11. Zai A, Rudd MA, Scribner AW, Loscalzo J. Cell-surface protein disulfde isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest. 1999;103:393-399.
12. Lyles MM, Gilbert HF. Catalysis of the oxidative folding of ribonucle-ase A by protein disulfde isomerase: pre-steady-state kinetics and the utilization of the oxidizing equivalents of the isomerase. Biochemistry. 1991;30:619-625.
13. Chen K, Detwiler TC, Essex DW. Characterization of protein disul-phide isomerase released from activated platelets. Br J Haematol. 1995;90:425-431.
14. Wan SW, Lin CF, Lu YT, Lei HY, Anderson R, Lin YS. Endothelial cell surface expression of protein disulfde isomerase activates β1 and β3 integrins and facilitates dengue virus infection. J Cell Biochem. 2012;113:1681-1691.
15. Thon JN, Peters CG, Machlus KR, Aslam R, Rowley J, Macleod H, Devine MT, Fuchs TA, Weyrich AS, Semple JW, Flaumenhaft R, Italiano JE Jr. T granules in human platelets function in TLR9 organization and signaling. J Cell Biol. 2012;198:561-574.
16. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfde isomerase is required for thrombus formation in vivo. Blood. 2010;116:4665-4674.
17. Cho J, Kennedy DR, Lin L, Huang M, Merrill-Skoloff G, Furie BC, Furie B. Protein disulfde isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins. Blood. 2012;120:647-655.
18. Hotchkiss KA, Chesterman CN, Hogg PJ. Catalysis of disulfde isomeri-zation in thrombospondin 1 by protein disulfde isomerase. Biochemistry. 1996;35:9761-9767.
19. Huang EM, Detwiler TC, Milev Y, Essex DW. Thiol-disulfde isomeri-zation in thrombospondin: effects of conformation and protein disulfde isomerase. Blood. 1997;89:3205-3212.
20. Burgess JK, Hotchkiss KA, Suter C, Dudman NP, Szöllösi J, Chesterman CN, Chong BH, Hogg PJ. Physical proximity and functional association of glycoprotein 1balpha and protein-disulfde isomerase on the platelet plasma membrane. J Biol Chem. 2000;275:9758-9766.
21. Lahav J, Wijnen EM, Hess O, Hamaia SW, Griffths D, Makris M, Knight CG, Essex DW, Farndale RW. Enzymatically catalyzed disulfde exchange is required for platelet adhesion to collagen via integrin alpha2beta1. Blood. 2003;102:2085-2092.
22. Essex DW, Li M, Miller A, Feinman RD. Protein disulfde isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry. 2001;40:6070-6075.
23. Essex DW, Miller A, Swiatkowska M, Feinman RD. Protein disul-fde isomerase catalyzes the formation of disulfde-linked complexes of vitronectin with thrombin-antithrombin. Biochemistry. 1999;38: 10398-10405.
24. Milev Y, Essex DW. Protein disulfde isomerase catalyzes the formation of disulfde-linked complexes of thrombospondin-1 with thrombin-anti-thrombin III. Arch Biochem Biophys. 1999;361:120-126.
25. Essex DW, Li M. Protein disulphide isomerase mediates platelet aggregation and secretion. Br J Haematol. 1999;104:448-454.
26. Manickam N, Sun X, Li M, Gazitt Y, Essex DW. Protein disulphide isom-erase in platelet function. Br J Haematol. 2008;140:223-229.
27. Kim K, Hahm E, Li J, Holbrook LM, Sasikumar P, Stanley RG, Ushio-Fukai M, Gibbins JM, Cho J. Platelet protein disulfde isomerase is required for thrombus formation but not for hemostasis in mice. Blood. 2013;122:1052-1061.
28. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfde isomerase during thrombus formation in mice. J Clin Invest. 2008;118:1123-1131.
29. Jasuja R, Passam FH, Kennedy DR, Kim SH, van Hessem L, Lin L, Bowley SR, Joshi SS, Dilks JR, Furie B, Furie BC, Flaumenhaft R. Protein disulfde isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest. 2012;122:2104-2113.
30. Walsh JD, Geczy CL. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost. 1991;66:552-558.
31. Le DT, Rapaport SI, Rao LV. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem. 1992;267:15447-15454.
32. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfde bond. Biochemistry. 2006;45:12020-12028.
33. Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W. Disulfde isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA. 2006;103:13932-13937.
34. Reinhardt C, von Brühl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, Engelmann B. Protein disulfde isomerase acts as an injury response signal that enhances fbrin generation via tissue factor activation. J Clin Invest. 2008;118:1110-1122.
35. Pendurthi UR, Ghosh S, Mandal SK, Rao LV. Tissue factor activation: is disulfde bond switching a regulatory mechanism? Blood. 2007;110:3900-3908.
36. Kothari H, Nayak RC, Rao LV, Pendurthi UR. Cystine 186-cystine 209 disulfde bond is not essential for the procoagulant activity of tissue factor or for its de-encryption. Blood. 2010;115:4273-4283.
37. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfde isomerase independent of oxidoreductase activity. J Biol Chem. 2007;282:25416-25424.
38. Furlan-Freguia C, Marchese P, Gruber A, Ruggeri ZM, Ruf W. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest. 2011;121:2932-2944.
39. Jurk K, Lahav J, VAN Aken H, Brodde MF, Nofer JR, Kehrel BE. Extracellular protein disulfde isomerase regulates feedback activation of platelet thrombin generation via modulation of coagulation factor binding. J Thromb Haemost. 2011;9:2278-2290.
40. Appenzeller-Herzog C, Ellgaard L. The human PDI family: versatility packed into a single fold. Biochim Biophys Acta. 2008;1783:535-548.
41. Mandel R, Ryser HJ, Ghani F, Wu M, Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfde-isomerase. Proc Natl Acad Sci USA. 1993;90:4112-4116.
42. Primm TP, Gilbert HF. Hormone binding by protein disulfde isomerase, a high capacity hormone reservoir of the endoplasmic reticulum. J Biol Chem. 2001;276:281-286.
43. Khan MM, Simizu S, Lai NS, Kawatani M, Shimizu T, Osada H. Discovery of a small molecule PDI inhibitor that inhibits reduction of HIV-1 envelope glycoprotein gp120. ACS Chem Biol. 2011;6:245-251.
44. Banerjee R, Pace NJ, Brown DR, Weerapana E. 1, 3, 5-Triazine as a modular scaffold for covalent inhibitors with streamlined target identifcation. J Am Chem Soc. 2013;135:2497-2500.
45. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfde isomerase for ovarian cancer treatment. Proc Natl Acad Sci USA. 2012;109:16348-16353.
46. Ge J, Zhang CJ, Li L, Chong LM, Wu X, Hao P, Sze SK, Yao SQ. Small molecule probe suitable for in situ profling and inhibition of protein disul-fde isomerase. ACS Chem Biol. 2013;8:2577-2585.
47. Muchowicz A, Firczuk M, Chlebowska J, Nowis D, Stachura J, Barankiewicz J, Trzeciecka A, Kłossowski S, Ostaszewski R, Zagozdzon R, Pu JX, Sun HD, Golab J. Adenanthin targets proteins involved in the regulation of disulphide bonds. Biochem Pharmacol. 2014;89: 210-216.
48. Xu S, Sankar S, Neamati N. Protein disulfde isomerase: a promising target for cancer therapy. Drug Discov Today. 2014;19:222-240.
49. VerPlank L, Khodier C, Nag PP, et al. Identifcation of ML359 as a Small Molecule Inhibitor of Protein Disulfde Isomerase. Probe Reports From the NIH Molecular Libraries Program. Bethesda, MD: National Center for Biotechnology Information (US); 2010.
50. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr. 2007;85:895-909.
51. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant favonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007-1011.
52. Hollman PC, van Trijp JM, Buysman MN, van der Gaag MS, Mengelers MJ, de Vries JH, Katan MB. Relative bioavailability of the anti-oxidant favonoid quercetin from various foods in man. FEBS Lett. 1997;418:152-156.
53. Gee JM, DuPont MS, Day AJ, Plumb GW, Williamson G, Johnson IT. Intestinal transport of quercetin glycosides in rats involves both degly-cosylation and interaction with the hexose transport pathway. J Nutr. 2000;130:2765-2771.
54. Walle T, Otake Y, Walle UK, Wilson FA. Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr. 2000;130:2658-2661.
55. Mullen W, Edwards CA, Crozier A. Absorption, excretion and metabolite profling of methyl-, glucuronyl-, glucosyl-and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr. 2006;96:107-116.
56. Sesink AL, O'Leary KA, Hollman PC. Quercetin glucuronides but not glucosides are present in human plasma after consumption of quercetin-3-glucoside or quercetin-4'-glucoside. J Nutr. 2001;131:1938-1941.
57. Heinz SA, Henson DA, Austin MD, Jin F, Nieman DC. Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. Pharmacol Res. 2010;62:237-242.
58. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012;95:454-464.
59. Huxley RR, Neil HA. The relation between dietary favonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003;57:904-908.
60. Knekt P, Kumpulainen J, Järvinen R, Rissanen H, Heliövaara M, Reunanen A, Hakulinen T, Aromaa A. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002;76:560-568.
61. Hirvonen T, Pietinen P, Virtanen M, Ovaskainen ML, Häkkinen S, Albanes D, Virtamo J. Intake of favonols and favones and risk of coronary heart disease in male smokers. Epidemiology. 2001;12:62-67.
62. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary favonoids, anti-oxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med. 1996;156:637-642.
63. Hollman PC, Geelen A, Kromhout D. Dietary favonol intake may lower stroke risk in men and women. J Nutr. 2010;140:600-604.
64. Wright B, Moraes LA, Kemp CF, Mullen W, Crozier A, Lovegrove JA, Gibbins JM. A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related favonoids. Br J Pharmacol. 2010;159:1312-1325.
65. Mulvihill EE, Huff MW. Antiatherogenic properties of favonoids: implications for cardiovascular health. Can J Cardiol. 2010;26(Suppl A):17A-21A.
66. Stopa J, Furie B, Flaumenhaft R, Zwicker J. Human clinical trials evaluating protein disulfde isomerase as an antithrombotic target: pharmacodynamic and pharmacokinetic studies of oral quercetin and isoquercetin. XXIV Congress of the International Society of Thrombosis and Haemostasis. Translational Research; 2013.
67. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15:6830-6840.
68. Ay C, Simanek R, Vormittag R, Dunkler D, Alguel G, Koder S, Kornek G, Marosi C, Wagner O, Zielinski C, Pabinger I. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112:2703-2708.